A citizen petition filed by an unnamed pharma company seeks changes to the FDA’s policy of publishing complete response letters for drugs and biologics that fail to gain approval. The petition argues the disclosure process lacks a clear mechanism for companies to respond before publication and raises concerns that trade secrets and proprietary information could be revealed. The FDA’s “radical transparency” initiative has already expanded its public CRL trove to more than 300 letters, and the investment community has previously viewed the move as positive for accountability. In contrast, the petition frames CRL disclosure as a potential legal and competitive risk. The dispute lands in a live policy arena where industry groups are increasingly focused on balancing transparency with data confidentiality—an issue that can affect how sponsors manage resubmissions and disclosure strategies.